摘要
近期由于有证据表明环氧合酶(Cox 2)抑制剂Celebrex(西乐葆)和非Cox 2抑制剂的非甾体类抗炎药物(NSAIDs)奈普生可增加心血管事件风险,美国食品及药物管理局(FDA)发布声明,停止这两个药物的临床试验,还建议正在服用非处方药物奈普生的患者应认真遵循说明书的指示。辉瑞公司建议医生在选择治疗关节炎或疼痛的药物时,应考虑替代治疗。心血管界非常关注此事件的进展。
Food and Drug Administration (FDA) has suspended the use of both celecoxib (Celebrex, Pfizer) and naproxen (Aleve, Bayer) in prevention large clinical trials after discovering that celecoxib and naproxen appeared to increase the risk of cardiovascular events with patients on placebo. FDA also advises patients who are currently taking over the counter naproxen products to carefully follow the instructions on the label. Pfizer suggested that alternatives to celecoxib should be considered based on individual patient needs and risk. The cardiovascular community responds differently.
出处
《中国循证医学杂志》
CSCD
2005年第1期6-7,共2页
Chinese Journal of Evidence-based Medicine
